Select Bibliography

Filter by any of these (after searching):

CALGB-59804

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann Oncol - 2007

Manuscript - Primary - Primary - Lymphoma - CALGB-59804

A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804

Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary - Primary - Lymphoma - CALGB-59804

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.

Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk Lymphoma - 2008

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804